Olink Proteomics Solutions – Targeted Assays by Sample, Disease, Species & Application

Olink's Plasma & Serum Proteome Assay offers precise quantification of proteins in blood-based samples, providing insights into systemic biology and disease mechanisms.

These assays are ideal for biomarker discovery, patient stratification, and disease profiling, offering a comprehensive overview of circulating protein biomarkers across various conditions.

Common Applications:

• Biomarker Discovery: Identify and validate disease-specific biomarkers, such as those linked to cardiovascular health, metabolic disorders, and immune function.
• Disease Profiling: Monitor protein expression patterns to distinguish between disease stages and track therapeutic response in diseases such as cancer, diabetes, and inflammatory conditions.
• Precision Medicine: Enable tailored treatment strategies by profiling proteins that correlate with patient outcomes.

Body Fluid Samples Proteome Assay expands Olink's high-throughput capabilities to a variety of less accessible biological fluids, such as cerebrospinal fluid (CSF), urine, and synovial fluid. These assays are particularly valuable when studying disease biomarkers that are present in low concentrations or in more difficult-to-access compartments.

Advantages for Rare or Hard-to-Collect Samples:

• Cerebrospinal Fluid (CSF): Profile proteins involved in neurodegeneration, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis.
• Urine & Synovial Fluid: Detect biomarkers related to kidney function, autoimmune diseases, and joint inflammation.
• Non-invasive Monitoring: Collecting urine or synovial fluid is less invasive than blood draws, enabling repeated sample collection in longitudinal studies.

These assays offer exceptional sensitivity, enabling the detection of low-abundance proteins critical for early diagnosis and monitoring of disease progression.

For research requiring tissue-specific proteomics, Olink's Tissue Sample Proteome Assay offers powerful tools to quantify proteins directly from tissue homogenates. These assays enable researchers to investigate the molecular biology of disease at the tissue level, providing deeper insights into cellular and sub-cellular pathways.

Benefits for Tissue-Specific Proteomics:

• Disease Mechanism Exploration: Study tissue-specific protein alterations in diseases such as cancer, fibrosis, and neurodegeneration.
• Target Identification: Identify novel therapeutic targets within specific tissue types for more precise drug development strategies.
• Target Engagement: Assess the impact of drug candidates directly within relevant tissues, helping determine efficacy and optimize dosing.

Olink's Cell Culture Proteome Assay is designed for cell-based research, offering a powerful tool for studying protein expression in culture supernatants or cell lysates. These assays are essential for researchers investigating protein secretion, cellular signaling, and responses to experimental treatments.

Application in Cell-Based Research:

• Drug Screening: Use cell-based assays to test the effects of new compounds on protein expression, particularly in the context of cancer, inflammation, or immune responses.
• Signal Transduction Studies: Investigate proteins involved in key pathways such as apoptosis, cell cycle regulation, and signal transduction.
• Biomarker Validation: Confirm the presence of candidate biomarkers from in vitro studies before progressing to animal or human models.

The Aging Proteome Assay from Olink provides critical insights into the molecular changes associated with aging and age-related diseases. This assay enables the profiling of biomarkers linked to immunosenescence, chronic inflammation, and tissue degradation—hallmarks of aging.

Biomarkers for Aging Research:

• Immunosenescence: Measure immune system decline and the accumulation of senescent cells that contribute to aging-related diseases like cardiovascular diseases, neurodegeneration, and cancer.
• Chronic Inflammation: Monitor the long-term inflammatory responses that play a role in age-related conditions such as osteoarthritis and Alzheimer's disease.
• Cellular Senescence: Track biomarkers indicating the accumulation of dysfunctional cells, which promote tissue damage and age-related functional decline.

By measuring these biomarkers, researchers can explore novel interventions that slow aging and mitigate the effects of chronic diseases in elderly populations.

Olink's Metabolic Diseases Proteome Assay is designed to provide a comprehensive view of the molecular pathways involved in metabolic disorders, including diabetes, obesity, and cardiovascular diseases. These diseases are often interlinked, driven by common underlying mechanisms such as insulin resistance and lipid metabolism disruptions.

Specific Applications in Diabetes, Obesity, and Cardiovascular Research:

• Diabetes: Profile proteins involved in insulin signaling, glucose metabolism, and inflammation to identify biomarkers for early detection and therapeutic monitoring.
• Obesity: Investigate adipocyte function, energy expenditure, and lipid metabolism pathways to uncover novel targets for weight management therapies.
• Cardiovascular Disease: Explore proteins linked to vascular inflammation, atherosclerosis, and myocardial function, providing valuable insights for heart disease research and drug development.

This assay is ideal for researchers aiming to identify biomarkers for early detection, track disease progression, and develop targeted therapies for these widespread metabolic diseases.

The Neurology Proteome Assay offers a powerful tool for the analysis of neurodegenerative diseases, neuroinflammation, and synaptic health. This assay enables the identification of biomarkers associated with conditions like Alzheimer's disease, Parkinson's disease, and multiple sclerosis—critical for early diagnosis and treatment strategies.

Biomarkers for Neurodegenerative Diseases and CNS Research:

• Alzheimer's Disease: Identify key proteins involved in amyloid plaque formation, tau pathology, and neuroinflammation that contribute to cognitive decline.
• Parkinson's Disease: Track proteins related to dopamine production, neuronal survival, and oxidative stress in the context of Parkinson's disease.
• Multiple Sclerosis: Quantify markers of immune activation, blood-brain barrier disruption, and neuronal damage in patients with MS.

These biomarkers are crucial for understanding disease mechanisms and monitoring treatment responses, accelerating the development of targeted therapies for CNS disorders.

The Oncology Proteome Assay is specifically designed to profile the complex molecular landscape of cancer, including tumor biology, immune response, and therapy resistance. This panel offers high-sensitivity detection of cancer-related proteins, facilitating early detection, tumor monitoring, and personalized treatment strategies.

Profiling Tumor Biology, Cancer Pathways, and Immune Interactions:

• Tumor Progression: Profile key oncogenes, tumor suppressor proteins, and angiogenesis markers that drive cancer cell growth, survival, and metastasis.
• Immune Response: Measure immune checkpoint proteins, cytokines, and chemokines to assess immune–tumor interactions and predict patient response to immunotherapy.
• Drug Resistance: Identify protein markers linked to therapy resistance, enabling the development of more effective, individualized cancer treatments.

With comprehensive coverage of cancer pathways, this assay supports both basic cancer research and clinical trials aimed at improving cancer therapies.

The Human Proteome Assay delivers high-sensitivity profiling of clinically relevant proteins, supporting research from early biomarker discovery to translational validation.

By covering thousands of biologically significant proteins, this assay enables researchers to investigate human disease biology at both the systemic and molecular level.

Focus on Human-Specific Biomarker Discovery and Disease Research:

• Detect and quantify low-abundance proteins in plasma, serum, CSF, urine, and tissue samples.
• Support precision medicine by identifying protein signatures that predict disease risk or therapy response.
• Validate biomarkers for use in clinical trials and patient stratification.

With proven reproducibility and cross-study comparability, this assay is ideal for projects aimed at bridging laboratory discoveries with real-world clinical applications.

The Mouse Proteome Assay is optimised for preclinical research, enabling robust biomarker discovery, disease mechanism studies, and therapeutic evaluation in mouse models.

This species-specific design ensures accurate quantification of mouse proteins, avoiding the cross-reactivity challenges common with human-targeted assays.

Validation for Preclinical Mouse Studies, Particularly Oncology and Immunology:

• Profile immune system activation and inflammatory pathways in mouse models of cancer, autoimmunity, or infection.
• Evaluate drug efficacy, pharmacodynamics, and toxicity during preclinical testing.
• Monitor longitudinal biomarker changes to assess disease progression or treatment response.

This assay is particularly valuable for translational research projects where findings in mice need to be reliably correlated to human biology.

The Horse Proteome Assay addresses the specialised needs of equine research, providing sensitive and reproducible protein profiling for veterinary science, sports medicine, and animal health research.

Specialised Assays for Equine Research in Immunology and Other Fields:

• Investigate immune system responses in horses affected by infectious diseases or inflammatory conditions.
• Study metabolic and cardiovascular biomarkers in the context of performance, endurance, or age-related decline.
• Support breeding programmes by profiling proteins linked to reproductive health and genetic traits.

With the ability to work from small sample volumes, this assay is particularly well-suited to longitudinal monitoring in valuable or hard-to-sample animals.

Olink's Protein Biomarker Profiling solutions enable comprehensive analysis of protein expression patterns across hundreds to thousands of targets in a single run.

This approach is essential for identifying, validating, and monitoring biomarkers that drive disease progression, treatment response, or physiological changes.

Overview of the Role in Identifying Disease-Specific Biomarkers:

• Screen for novel biomarkers in discovery-phase studies.
• Compare protein signatures across patient subgroups for precision medicine research.
• Monitor longitudinal changes to assess treatment impact or disease recurrence.

By leveraging high-sensitivity PEA technology, researchers can detect even low-abundance biomarkers that may be missed by traditional immunoassays.

The Disease Classification application harnesses Olink's multiplex protein profiling to distinguish between disease subtypes based on unique protein expression patterns.

This approach supports both fundamental research and clinical trial stratification, helping to ensure that interventions target the right patient populations.

How Olink's Technology Aids in Classification:

• Map protein expression patterns associated with specific disease phenotypes.
• Identify molecular subtypes within heterogeneous conditions such as cancer, autoimmune disorders, and neurodegenerative diseases.
• Support diagnostic and prognostic model development by integrating proteomics with genomic and clinical data.

These insights help researchers refine hypotheses, improve trial design, and accelerate the translation of laboratory findings into clinical benefit.

In Drug Development, Olink assays provide actionable protein biomarker data to guide decision-making throughout the therapeutic pipeline—from target identification to post-market surveillance.

Applications in Evaluating Drug Efficacy, Target Identification, and Therapeutic Biomarkers:

• Target Identification: Pinpoint proteins directly implicated in disease mechanisms to guide candidate selection.
• Mechanism-of-Action Studies: Understand how a drug impacts relevant biological pathways at the protein level.
• Efficacy and Safety Monitoring: Track biomarkers that indicate therapeutic response or potential adverse effects.
• Companion Diagnostics Development: Develop protein-based assays to predict treatment benefit in specific patient groups.

Olink's high reproducibility and minimal sample requirements make it ideal for longitudinal monitoring, large-scale cohort studies, and adaptive trial designs.